Aadi bioscience announces first patient dosed in its precision 1 phase 2 registrational trial of nab-sirolimus in patients with solid tumors harboring pathogenic inactivating alterations in tsc1 and tsc2 genes

Fda grants fast track designation for nab-sirolimus for the treatment of adult and adolescent patients with tuberous sclerosis complex 1 and 2 (“tsc1” and “tsc2”) alterations fda grants fast track designation for nab-sirolimus for the treatment of adult and adolescent patients with tuberous sclerosis complex 1 and 2 (“tsc1” and “tsc2”) alterations
AADI Ratings Summary
AADI Quant Ranking